Silexion Therapeutics Corp SLXN
NASDAQ · United States · Health Technology
$0.2790+0.00 (+0.61%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| LTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Interest & dividend income | $155.00K | $155.00K | $28.00K | $153.00K |
| Interest expense | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Net interest income | $153.00K | $142.00K | $1.00K | $153.00K |
| Operating expenses | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Pre-tax income | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Income tax | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Net Income | -$13.96M | -$11.91M | -$16.52M | -$5.11M |
| Diluted EPS | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Assets | $4.25M | $7.22M | $2.86M | $5.26M |
| Total Liabilities | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| LTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash from Operations | -$12.43M | -$10.82M | -$8.40M | -$4.53M |
| Cash from Investing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO | MakklerPRO | MakklerPRO |
Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice. This company reports on a bank/financial-institution template: the income statement is built on an interest spread rather than on sales, and the balance sheet has no current/non-current split. The "Total revenue (net)" line is net interest income plus non-interest income; providers define revenue differently for lenders, so this figure may not match the "revenue" shown elsewhere.